Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Neuropathic Pain Therapeutics Market


4. Market Overview

4.1. Introduction & Overview

4.2. Product Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018–2030


5. Market Outlook

5.1. Pipeline Analysis

5.2. Treatment Guidelines

5.3. COVID-19 Pandemics Impact on Industry


6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

6.2.1. Anticonvulsants

6.2.2. Antidepressants

6.2.2.1. Tricyclic Antidepressants

6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

6.2.3. NSAIDs

6.2.4. Opioids

6.2.5. Steroids

6.2.6. Others

6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class


7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication

7.1. Introduction & Definition

7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018–2030

7.2.1. Diabetic Neuropathy

7.2.2. Post-herpetic Neuralgia

7.2.3. Cancer-related Pain

7.2.4. Spinal Cord Injury

7.2.5. Others

7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication


8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018–2030

8.2.1. Oral

8.2.2. Topical

8.2.3. Others

8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration


9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition

9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

9.2.1. Hospital Pharmacies

9.2.2. Retail Pharmacies

9.2.3. Online Pharmacies

9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel


10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region

10.1. Key Findings

10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region


11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast

11.1. Introduction

11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

11.2.1. Anticonvulsants

11.2.2. Antidepressants

11.2.2.1. Tricyclic Antidepressants

11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

11.2.3. NSAIDs

11.2.4. Opioids

11.2.5. Steroids

11.2.6. Others

11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

11.3.1. Diabetic Neuropathy

11.3.2. Post-herpetic Neuralgia

11.3.3. Cancer-related Pain

11.3.4. Spinal Cord Injury

11.3.5. Others

11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

11.4.1. Oral

11.4.2. Topical

11.4.3. Others

11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

11.6.1. U.S.

11.6.2. Canada

11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis

11.7.1. By Drug Class

11.7.2. By Indication

11.7.3. By Route of Administration

11.7.4. By Distribution Channel

11.7.5. By Country


12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast

12.1. Introduction

12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

12.2.1. Anticonvulsants

12.2.2. Antidepressants

12.2.2.1. Tricyclic Antidepressants

12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

12.2.3. NSAIDs

12.2.4. Opioids

12.2.5. Steroids

12.2.6. Others

12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

12.3.1. Diabetic Neuropathy

12.3.2. Post-herpetic Neuralgia

12.3.3. Cancer-related Pain

12.3.4. Spinal Cord Injury

12.3.5. Others

12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

12.4.1. Oral

12.4.2. Topical

12.4.3. Others

12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies

12.5.3. Online Pharmacies

12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Rest of Europe

12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis

12.7.1. By Drug Class

12.7.2. By Indication

12.7.3. By Route of Administration

12.7.4. By Distribution Channel

12.7.5. By Country/Sub-region

13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast

13.1. Introduction

13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

13.2.1. Anticonvulsants

13.2.2. Antidepressants

13.2.2.1. Tricyclic Antidepressants

13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

13.2.3. NSAIDs

13.2.4. Opioids

13.2.5. Steroids

13.2.6. Others

13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

13.3.1. Diabetic Neuropathy

13.3.2. Post-herpetic Neuralgia

13.3.3. Cancer-related Pain

13.3.4. Spinal Cord Injury

13.3.5. Others

13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

13.4.1. Oral

13.4.2. Topical

13.4.3. Others

13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies

13.5.3. Online Pharmacies

13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

13.6.1. China

13.6.2. Japan

13.6.3. India

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis

13.7.1. By Drug Class

13.7.2. By Indication

13.7.3. By Route of Administration

13.7.4. By Distribution Channel

13.7.5. By Country/Sub-region

14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast

14.1. Introduction

14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

14.2.1. Anticonvulsants

14.2.2. Antidepressants

14.2.2.1. Tricyclic Antidepressants

14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

14.2.3. NSAIDs

14.2.4. Opioids

14.2.5. Steroids

14.2.6. Others

14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

14.3.1. Diabetic Neuropathy

14.3.2. Post-herpetic Neuralgia

14.3.3. Cancer-related Pain

14.3.4. Spinal Cord Injury

14.3.5. Others

14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

14.4.1. Oral

14.4.2. Topical

14.4.3. Others

14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies

14.5.3. Online Pharmacies

14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis

14.7.1. By Drug Class

14.7.2. By Indication

14.7.3. By Route of Administration

14.7.4. By Distribution Channel

14.7.5. By Country/Sub-region


15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast

15.1. Introduction

15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

15.2.1. Anticonvulsants

15.2.2. Antidepressants

15.2.2.1. Tricyclic Antidepressants

15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

15.2.3. NSAIDs

15.2.4. Opioids

15.2.5. Steroids

15.2.6. Others

15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

15.3.1. Diabetic Neuropathy

15.3.2. Post-herpetic Neuralgia

15.3.3. Cancer-related Pain

15.3.4. Spinal Cord Injury

15.3.5. Others

15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

15.4.1. Oral

15.4.2. Topical

15.4.3. Others

15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies

15.5.3. Online Pharmacies

15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis

15.7.1. By Drug Class

15.7.2. By Indication

15.7.3. By Route of Administration

15.7.4. By Distribution Channel

15.7.5. By Country/Sub-region


16. Competition Landscape

16.1. Competition Matrix

16.2. Market Share Analysis, by Company, 2019

16.3. Company Profiles

16.3.1. Novartis AG

16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.1.2. Company Financials

16.3.1.3. Growth Strategies

16.3.1.4. SWOT Analysis

16.3.2. GlaxoSmithKline plc

16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.2.2. Company Financials

16.3.2.3. Growth Strategies

16.3.2.4. SWOT Analysis

16.3.3. AstraZeneca

16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.3.2. Company Financials

16.3.3.3. Growth Strategies

16.3.3.4. SWOT Analysis

16.3.4. Pfizer, Inc.

16.3.4.1. Company Overview (HQ, Business Segments)

16.3.4.2. Company Financials

16.3.4.3. Growth Strategies

16.3.4.4. SWOT Analysis

16.3.5. Eli Lilly and Company

16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.5.2. Company Financials

16.3.5.3. Growth Strategies

16.3.5.4. SWOT Analysis

16.3.6. Mallinckrodt Pharmaceuticals

16.3.6.1. Company Overview (HQ, Business Segments)

16.3.6.2. Company Financials

16.3.6.3. Growth Strategies

16.3.6.4. SWOT Analysis

16.3.7. Johnson & Johnson

16.3.7.1. Company Overview (HQ, Business Segments)

16.3.7.2. Company Financials

16.3.7.3. Growth Strategies

16.3.7.4. SWOT Analysis

16.3.8. Abbott

16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.8.2. Company Financials

16.3.8.3. Growth Strategies

16.3.8.4. SWOT Analysis

16.3.9. Endo Pharmaceuticals, Inc.

16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.9.2. Company Financials

16.3.9.3. Growth Strategies

16.3.9.4. SWOT Analysis

16.3.10. Teva Pharmaceutical Industries Limited

16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.10.2. Company Financials

16.3.10.3. Growth Strategies

16.3.10.4. SWOT Analysis

16.3.11. Merck & Co., Inc.

16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.11.2. Company Financials

16.3.11.3. Growth Strategies

16.3.11.4. SWOT Analysis



List of Figures



Figure 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030

Figure 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, 2018–2030

Figure 03: Market Value Share, by Drug Class, 2019

Figure 04: Market Value Share, by Disease Type, 2019

Figure 05: Market Value Share, by Route of Administration, 2019

Figure 06: Market Value Share, by Distribution Channel, 2019

Figure 07: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 08: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2018–2020

Figure 09: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antidepressants, 2018–2020

Figure 10: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NSAIDs, 2018–2020

Figure 11: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Opioids, 2018–2020

Figure 12: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Steroids, 2018–2020

Figure 13: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 14: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 15: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 16: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetic Neuropathy, 2018–2020

Figure 17: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Post-herpetic Neuralgia, 2018–2020

Figure 18: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer-related Pain, 2018–2020

Figure 19: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Spinal Cord Injury, 2018–2020

Figure 20: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 21: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 22: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 23: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2018–2020

Figure 24: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2018–2020

Figure 25: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020

Figure 26: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 27: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 28: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2030

Figure 29: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2030

Figure 30: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018–2030

Figure 31: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 32: Global Neuropathic Pain Therapeutics Market, by Region, 2019 and 2030

Figure 33: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region, 2020–2030

Figure 34: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 35: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 36: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 37: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 38: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 39: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 40: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 41: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 42: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 43: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country, 2019 and 2030

Figure 44: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country, 2020–2030

Figure 45: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 46: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 47: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 48: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 49: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 50: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 51: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 52: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 53: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 54: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 55: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 57: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 58: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 59: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 60: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 61: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 62: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 63: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 64: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 65: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 66: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 67: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 68: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 69: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 70: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 71: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 72: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 73: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 74: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 75: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 76: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 77: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 78: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 79: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 80: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 81: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030

Figure 82: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030

Figure 83: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 84: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 85: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 86: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 87: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 88: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030


List of Tables



Table 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030